Study Redefines Dopamine’s Role in Motor Control

A study led by McGill University challenges the long-standing idea that dopamine directly determines the speed or force of each movement. Published in Nature Neuroscience, the research suggests dopamine’s role is more foundational—it acts as the support system that allows movement to occur at all.

“Our findings suggest we should rethink dopamine’s role in movement,” said senior author Nicolas Tritsch. “Restoring dopamine to a normal level may be enough to improve movement. That could simplify how we think about Parkinson’s treatment.”

Dopamine has long been associated with motor vigor, the ability to move with strength and speed. In Parkinson’s disease, neurons that produce dopamine degenerate, leading to tremors, slower motion, and imbalance. The standard treatment, Levodopa, helps patients move more freely, yet the exact reason it works has been uncertain. Studies have shown quick bursts of dopamine activity during motion, which many thought controlled how vigorous a movement would be.

The McGill-led research presents a different view. As Tritsch explained, “Rather than acting as a throttle that sets movement speed, dopamine appears to function more like engine oil. It’s essential for the system to run, but not the signal that determines how fast each action is executed.”

The team tested this by measuring brain activity in mice trained to press a weighted lever. Using light to turn dopamine cells “on” or “off” in real time, they observed that changing dopamine levels during movement did not affect the animals’ speed or strength. When testing Levodopa, they discovered the drug worked by restoring baseline dopamine levels rather than the rapid bursts once thought crucial for controlling motion.

Understanding dopamine’s true function offers a clearer picture of why Levodopa helps and could refine current approaches. Maintaining stable dopamine levels may be more important than replicating natural fluctuations.

The findings also suggest revisiting other therapies. Dopamine receptor agonists have shown potential but caused side effects because they acted too broadly. Insights from this study could help researchers design more precise treatments that target the right aspects of dopamine signaling.